Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

Sara A. Hurvitz, Miguel Martin, W. Fraser Symmans, Kyung Hae Jung, Chiun Sheng Huang, Alastair M. Thompson, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Mario Campone, Jean François Boileau, Matthias W. Beckmann, Karen Afenjar, Rodrigo Fresco, Hans Joachim Helms, Jin Xu, Yvonne G. Lin, Joseph Sparano, Dennis Slamon

Research output: Contribution to journalArticlepeer-review

148 Scopus citations

Fingerprint

Dive into the research topics of 'Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences